Takeshi Kato

7.9k total citations
294 papers, 4.2k citations indexed

About

Takeshi Kato is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Takeshi Kato has authored 294 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Oncology, 95 papers in Pulmonary and Respiratory Medicine and 63 papers in Cancer Research. Recurrent topics in Takeshi Kato's work include Colorectal Cancer Treatments and Studies (142 papers), Gastric Cancer Management and Outcomes (66 papers) and Cancer Genomics and Diagnostics (55 papers). Takeshi Kato is often cited by papers focused on Colorectal Cancer Treatments and Studies (142 papers), Gastric Cancer Management and Outcomes (66 papers) and Cancer Genomics and Diagnostics (55 papers). Takeshi Kato collaborates with scholars based in Japan, United States and China. Takeshi Kato's co-authors include Toshiharu Nagatsu, Kazuhiro Oka, Toshifumi Yamamoto, Takayuki Yoshino, Shumpei Sakakibara, Kohichi Kojima, Ikuko Nagatsu, Eiji Oki, Masamichí Okada and Toshiyuki Chikuma and has published in prestigious journals such as Science, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Takeshi Kato

268 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takeshi Kato Japan	35	2.1k	1.2k	926	680	651	294	4.2k
Masahide Ohmichi Japan	45	1.1k 0.5×	2.7k 2.2×	414 0.4×	382 0.6×	748 1.1×	226	6.1k
Kevin R. Kozak United States	36	797 0.4×	929 0.8×	404 0.4×	892 1.3×	597 0.9×	89	4.5k
Yuji Okada Japan	37	758 0.4×	1.3k 1.0×	338 0.4×	381 0.6×	306 0.5×	171	3.7k
Sanjay Jain United States	42	877 0.4×	3.1k 2.6×	543 0.6×	777 1.1×	743 1.1×	162	7.0k
Darren A.E. Cross United Kingdom	29	2.0k 0.9×	6.4k 5.3×	884 1.0×	1.3k 1.8×	714 1.1×	58	9.2k
Xuefeng Xia China	35	760 0.4×	2.8k 2.3×	761 0.8×	411 0.6×	551 0.8×	110	4.9k
Davide Franceschini Italy	33	711 0.3×	688 0.6×	343 0.4×	1.3k 2.0×	533 0.8×	182	3.7k
Kyung-Han Lee South Korea	35	701 0.3×	1.6k 1.3×	262 0.3×	846 1.2×	517 0.8×	244	5.3k
Diego Russo Italy	49	1.0k 0.5×	3.2k 2.6×	402 0.4×	320 0.5×	696 1.1×	188	7.5k

Countries citing papers authored by Takeshi Kato

Since Specialization

Citations

This map shows the geographic impact of Takeshi Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeshi Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeshi Kato more than expected).

Fields of papers citing papers by Takeshi Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeshi Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeshi Kato. The network helps show where Takeshi Kato may publish in the future.

Co-authorship network of co-authors of Takeshi Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Takeshi Kato. A scholar is included among the top collaborators of Takeshi Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeshi Kato. Takeshi Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bando, Hideaki, Yuichiro Tsukada, Su Jin Lee, et al.. (2025). 777P Spatial transcriptomic dynamics of the tumour microenvironment after chemoradiotherapy followed by immune checkpoint blockade in locally advanced rectal cancer: A translational study from VOLTAGE trial. Annals of Oncology. 36. S501–S501.

Kotani, Daisuke, Atsuo Takashima, Takeshi Kato, et al.. (2024). Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. Clinical Colorectal Cancer. 23(2). 174–182.e6. 3 indexed citations

Nakamura, Yoshiaki, Keiji Hirata, Naoya Akazawa, et al.. (2024). Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY.. Journal of Clinical Oncology. 42(16_suppl). 3609–3609.

Miyagaki, Hiromichi, Masahiro Goto, Shunji Endo, et al.. (2024). Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.. Journal of Clinical Oncology. 42(16_suppl). 4031–4031. 1 indexed citations

Uetake, Hiroyuki, Kohei Shitara, Takayuki Yoshino, et al.. (2024). Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.. Journal of Clinical Oncology. 42(16_suppl). 3507–3507. 2 indexed citations

Oki, Eiji, Ryota Nakanishi, Koji Ando, et al.. (2024). Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies. SHILAP Revista de lepidopterología. 3. 100034–100034. 1 indexed citations

Cutsem, Eric Van, Julien Taı̈eb, Rona Yaeger, et al.. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF^V600E-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 41(14). 2628–2637. 63 indexed citations

Kato, Takeshi, Hideaki Bando, Yuichiro Tsukada, et al.. (2023). P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer. Annals of Oncology. 34. S77–S77. 1 indexed citations

Kobayashi, Shin, Akio Shiomi, Akiko Takahashi, et al.. (2023). 591P Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based genomic profile and molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study. Annals of Oncology. 34. S428–S429. 4 indexed citations

10.

Kato, Takeshi, Atsuo Takashima, Taroh Satoh, et al.. (2023). P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study. Annals of Oncology. 34. S21–S22. 1 indexed citations

11.

Uemura, Mamoru, Yuta Kobayashi, Masaaki Miyo, et al.. (2022). Postoperative pain management after concomitant sacrectomy for locally recurrent rectal cancer. Surgery Today. 52(11). 1599–1606. 2 indexed citations

12.

Kotaka, Masahito, Takatsugu Ogata, Yukimasa Hatachi, et al.. (2020). Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. PLoS ONE. 15(6). e0234314–e0234314. 11 indexed citations

13.

Kotaka, Masahito, Shigeyoshi Iwamoto, Hironaga Satake, et al.. (2020). Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). International Journal of Clinical Oncology. 25(8). 1515–1522. 4 indexed citations

14.

Kotaka, Masahito, Yoji Saito, Takeshi Kato, et al.. (2020). Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy. Cancer Chemotherapy and Pharmacology. 87(4). 585–586. 2 indexed citations

15.

Kotaka, Masahito, Yoji Saito, Takeshi Kato, et al.. (2020). A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Cancer Chemotherapy and Pharmacology. 86(5). 607–618. 16 indexed citations

16.

Oki, Eiji, Takeshi Kato, Hideaki Bando, et al.. (2018). A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clinical Colorectal Cancer. 17(2). 147–155. 32 indexed citations

17.

Yoshino, Takayuki, Takeharu Yamanaka, Masahito Kotaka, et al.. (2017). Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. Annals of Oncology. 28. v614–v614. 6 indexed citations

18.

Yamamoto, Hirofumi, Kohei Murata, Mutsumi Fukunaga, et al.. (2016). Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. Clinical Cancer Research. 22(13). 3201–3208. 32 indexed citations

19.

Takeyama, Hiroshi, Hirofumi Yamamoto, Shinya Yamashita, et al.. (2014). Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer. Molecular Cancer Therapeutics. 13(4). 976–985. 64 indexed citations

20.

Shimada, Yasuhiro, Tetsuya Hamaguchi, Junki Mizusawa, et al.. (2014). Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205. European Journal of Cancer. 50(13). 2231–2240. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact